Disaggregated mutant human RANTES
AssigneeBritish Biotech Pharmaceuticals Limited
InventorsLloyd George Czaplewski, Michael George Hunter, Richard Mark Edwards, Keith Martyn Dawson
Life of this patent
Estimating the term…
Abstract
This invention relates to mutants of human RANTES (hRANTES) which, relative to the wild-type molecule, have a reduced tendency to aggregate into large multimeric complexes at physiological ionic strength and pH, and are less pro-inflammatory.
Claims4
A disaggregated mutant human RANTES chemokine molecule wherein the glutamic acid residue at position 26 of wild-type hRANTES, said wild-type hRANTES comprising the amino acid sequence set forth in SEQ ID NO:
- 1 is substituted by an alanine residue.
A disaggregated mutant human RANTES chemokine molecule wherein the glutamic acid residue at position 66 of wild-type RANTES, said wild-type hRANTES comprising the amino acid sequence set forth in SEQ ID NO:1. is substituted by a serine residue.
A disaggregated mutant human RANTES chemokine molecule wherein one or both of the residues at position 26 and 66 of wild-type hRANTES said wild-type hRANTES comprising the amino acid sequence set forth in SEQ ID NO:
- 1, is substituted by other amino acids, and wherein the mutant is incapable at physiological ionic strengh of forming a stable multimner greater than a dodecamer as determined by Sedimentation Equilibrium Analytical Ultracentrifugation (AUC).
A disaggregated mutant human RANTES chemokine molecule wherein the residues at positions 26 and 66 of wild-type hRANTES, said wild-type hRANTES comprising the amino acid sequence set forth in SEQ ID NO:1are substituted by alanine and serine, respectively.
Dependencies are inferred from the claim text.